Agreement with Bicycle and Cancer Research UK

8 July 2019

Physiomics plc

("Physiomics") or (the "Company")

Physiomics signs agreement with Bicycle Therapeutics and Cancer Research UK

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has signed an agreement to work with Bicycle Therapeutics and Cancer Research UK. The project is expected to be completed during this calendar year and will focus on the analysis of clinical data arising from the ongoing Cancer Research UK-sponsored Phase I/IIa clinical trial of Bicycle Therapeutics' lead program, BT1718, in solid tumours.

Dr Jim Millen, CEO said: "We are very pleased to be working on this second project with Bicycle Therapeutics and to be working for the first time directly with Cancer Research UK, the UK's leading cancer research charity."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.